Lyell Immunopharma, Inc.
LYEL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$342,994 | -$234,632 | -$183,118 | -$250,219 |
| Dep. & Amort. | $19,631 | $20,250 | $16,467 | $13,624 |
| Deferred Tax | $0 | $0 | $0 | $39,506 |
| Stock-Based Comp. | $33,144 | $0 | $0 | $62,201 |
| Change in WC | -$3,120 | $3,421 | -$82,015 | $4,015 |
| Other Non-Cash | $130,945 | $47,267 | $79,111 | $4,624 |
| Operating Cash Flow | -$162,394 | -$163,694 | -$169,555 | -$126,249 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$464 | -$2,686 | -$24,276 | -$65,504 |
| Net Acquisitions | -$31,346 | $0 | $0 | $673,465 |
| Inv. Purchases | -$394,707 | -$476,880 | -$406,316 | -$673,465 |
| Inv. Sales/Matur. | $548,941 | $663,614 | $419,052 | $617,396 |
| Other Inv. Act. | $0 | $0 | $0 | -$673,465 |
| Investing Cash Flow | $122,424 | $184,048 | -$11,540 | -$121,573 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $1,402 | $2,200 | $11,096 | $391,802 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$76 | -$457 | -$461 | $9,442 |
| Financing Cash Flow | $1,326 | $1,743 | $10,635 | $401,244 |
| Forex Effect | $0 | -$4 | $186 | $0 |
| Net Chg. in Cash | -$38,644 | $22,093 | -$170,274 | $153,422 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $145,931 | $123,554 | $293,828 | $140,872 |
| End Cash | $107,287 | $145,647 | $123,554 | $294,294 |
| Free Cash Flow | -$162,858 | -$166,380 | -$193,831 | -$191,753 |